We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Biomarker Predicts Cancer Aggressiveness and Drug Susceptibility

By LabMedica International staff writers
Posted on 24 Oct 2017
Researchers have identified a protein required by some forms of brain cancer (glioblastoma multiforme, GBM) that can be used as a predictive marker for aggressiveness and effective drug response.

Glioblastoma is the most common primary tumor of the central nervous system and is almost always fatal. The aggressive invasion of glioblastoma cells into the surrounding normal brain makes complete surgical removal impossible, significantly increases resistance to the standard therapy regimen, and virtually assures tumor recurrence. Treatment of glioblastoma usually comprises surgical removal of the tumor followed by radiation treatment and chemotherapy using the drug temozolomide (TMZ). However, the penetration of the tumor into adjacent brain tissue prevents the surgical removal of all tumor cells, which usually develop resistance to TMZ.

Image: A photomicrograph showing histopathological image of cerebral glioblastoma (Photo courtesy of Wikimedia Commons).
Image: A photomicrograph showing histopathological image of cerebral glioblastoma (Photo courtesy of Wikimedia Commons).

Investigators at Mount Sinai School of Medicine (New York, NY, USA) found that the mitotic spindle checkpoint protein BUB1B (serine/threonine-protein kinase BUB1 beta) may serve as a predictive marker for glioblastoma aggressiveness and effective drug response. BUB1B is a kinase involved in spindle checkpoint function and chromosome segregation. The protein has been localized to the kinetochore and plays a role in the inhibition of the anaphase-promoting complex/cyclosome (APC/C), delaying the onset of anaphase and ensuring proper chromosome segregation. Impaired spindle checkpoint function has been found in many forms of cancer.

The investigators used gene expression data from GBM stem-like cells, astrocytes, and neural progenitor cells that were sensitive or resistant to BUB1B inhibition to create a computational framework to predict sensitivity to BUB1B inhibition. Applying this framework to tumor expression data from patients, they stratified tumors into BUB1B-sensitive (BUB1BS) or BUB1B-resistant (BUB1BR) subtypes. Through this effort, they found that BUB1BS patients had a significantly worse prognosis regardless of tumor development subtype (i.e., classical, mesenchymal, neural, proneural). Functional genomic profiling of BUB1BR versus BUB1BS isolates revealed a differential reliance of genes enriched in the BUB1BS classifier, including those involved in mitotic cell cycle, microtubule organization, and chromosome segregation.

By comparing drug sensitivity profiles, the investigators predicted that BUB1BS cells would be more sensitive to type I and II topoisomerase inhibitors, Raf inhibitors, and other drugs, and experimentally validated some of these predictions.

“It was truly remarkable to see our predictive model yield a new set of molecular subtypes, which appear to be far more indicative of prognosis and therapeutic response than existing subtypes,” said senior author Dr. Jun Zhu, professor of genetics and genomic sciences at Mount Sinai Medical School. “For patients who receive the grim diagnosis of glioblastoma, this signals new hope for tailored treatment more likely to be effective against their cancer.”

The study was published in the October 15, 2017, issue of the journal Cancer Research.

Related Links:
Mount Sinai School of Medicine


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Latest Molecular Diagnostics News

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear